Abstract: An electrochromic device with side-by-side structure including a common electrode unit, at least one color-changing unit and an electrolyte layer is provided. The common electrode unit includes an electrode layer and an electrode protection layer disposed on the electrode layer. The color-changing unit includes a transparent conductive layer and a color-changing layer disposed on the transparent conductive layer. The common electrode unit and each color-changing unit are arranged on the same plane with an insulating region between two adjacent units. The electrolyte layer covers and connects the electrode protection layer of the common electrode unit and the color-changing layer of each color-changing unit.

Abstract: Disclosed herein is a simple and reproducible 3D-culture-based process for generating cardiac spheroids containing all four cardiac-cell types (cardiomyocytes, endothelial cells, smooth muscle cells, and cardiac fibroblasts) that is compatible with a wide range of applications and research equipment. Subsequent experiments demonstrated that the inclusion of vascular cells and cardiac fibroblasts was associated with an increase in spheroid size, a decline in apoptosis, an improvement in sarcomere maturation and a change in CM bioenergetics. These suggest a three-dimensional (3D) environment with endothelial cells, smooth muscle cells, and cardiac fibroblasts which promoted CM maturation and electrical activity.

Abstract: In one aspect, the disclosure relates to a synthetic modified mRNA (modRNA) and a novel gene therapy approach using the same that offers efficient, transient, safe, nonimmunogenic, and controlled mRNA delivery to the heart tissue without any risk of genomic integration. In a further aspect, the disclosure relates to methods of using the modRNA to achieve transient and exclusive overexpression of CCND2 only in cardiomyocytes, increasing cell cycle markers, enhancing cardiac function, and promoting myocardial repair. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: A finite time speed control method for a permanent magnet synchronous motor (PMSM) based on a fast integral terminal sliding mode and disturbance estimation comprises: firstly, determining a mathematical model of a speed loop of the PMSM under the influence of system parameters uncertainty and unknown load torque; secondly, designing an improved fast integral terminal sliding surface on the basis of the idea of terminal sliding mode control; then, proposing a disturbance estimation method based on an adaptive fuzzy system with respect to the disturbance in a PMSM system; designing a PMSM speed controller on this basis; and finally, completing the concrete implementation of the whole technical solution. The present invention designs the fast integral terminal sliding surface and a sliding mode control law to ensure that a motor speed tracking error converges to zero within finite time and enhances the rapidity of a PMSM speed regulating system.

Abstract: A speed control method for a permanent magnet synchronous motor considering current saturation and disturbance suppression aims to effectively ensure that a current of the motor is always within a given range to avoid the problem of control performance reduction caused by the fact that the current gets into a saturation state, ensure the safety of a system, do not need to use unavailable state variables such as motor acceleration and the like, effectively estimate and compensate disturbances including parameters uncertainty and unknown load torque disturbance existing in a permanent magnet synchronous motor system, and rapidly and accurately control a speed of the motor finally. There is no need to configure a plurality of sensors in practical industrial application, so system building costs can be reduced on the one hand, and the stability of the system can be improved on the other hand.

Abstract: In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.

Abstract: A robust position control method for a permanent magnet synchronous motor considering current limitation is provided. The method fully considers the influence of current limitation on a closed loop system in controller design, stability analysis and other theoretical analysis phase, can effectively overcome the influence of system disturbances including system parameters uncertainty and unknown load torque, and finally realize a control objective of accurate tracking of the motor position. More importantly, the technology is a continuous control method which can overcome the inherent chattering problem while having strong robustness of sliding mode control. Meanwhile, a controller designed by the present invention also has the advantages of simple structure, etc. The technical solution proposed by the present invention has wide practical application prospect due to the characteristics of excellent anti-disturbance capability, and simple and feasible structure.

Abstract: A robust position control method for a permanent magnet synchronous motor considering current limitation is provided. The method fully considers the influence of current limitation on a closed loop system in controller design, stability analysis and other theoretical analysis phase, can effectively overcome the influence of system disturbances including system parameters uncertainty and unknown load torque, and finally realize a control objective of accurate tracking of the motor position. More importantly, the technology is a continuous control method which can overcome the inherent chattering problem while having strong robustness of sliding mode control. Meanwhile, a controller designed by the present invention also has the advantages of simple structure, etc. The technical solution proposed by the present invention has wide practical application prospect due to the characteristics of excellent anti-disturbance capability, and simple and feasible structure.

Abstract: The present invention belongs to the technical field of permanent magnet synchronous motor control, and provides a speed control method for a permanent magnet synchronous motor considering current saturation and disturbance suppression, which aims to effectively ensure that a current of the motor is always within a given range to avoid the problem of control performance reduction caused by the fact that the current gets into a saturation state, ensure the safety of a system, do not need to use unavailable state variables such as motor acceleration and the like, effectively estimate and compensate disturbances including parameters uncertainty and unknown load torque disturbance existing in a permanent magnet synchronous motor system, and rapidly and accurately control a speed of the motor finally. There is no need to configure a plurality of sensors in practical industrial application, so system building costs can be reduced on the one hand, and the stability of the system can be improved on the other hand.

Abstract: A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.

Abstract: Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (??m) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.

Abstract: The invention discloses a method by which potential bioactive compounds from herbals can be identified by regrouping after chromatography. The method comprises the steps of: selecting herbals with reports of therapeutic effects according to previous experience, extracting compounds by boiling or chemical methods, and separating compounds with the chromatography. The separated compounds are regrouped with different portions, which are further tested in vivo and/or in vitro to remove the inactive portions and repeating the same process until no more compounds can be removed, and the remaining compounds are synthesized or purified, which are made into various forms and utilized to treat diseases.

Abstract: A system and method for acquiring and using inversion-recovery data and spectral data. In particular, the inversion-recovery data and spectral data can be used to determine adenosine triphosphate (ATP) hydrolysis rate of a subject without a quantification of inorganic phosphate.

Abstract: The invention discloses a method of treatment for various severe disorders which is not treated well by current FDA approved drugs. The therapeutic agents by the method are compounds or biological agents which pass safety tests in the clinical trials, but not pass the efficacy test, as safety of those compounds or biological agents are comparable with any ones in the market which pass both safety and efficacy tests in the clinical trials, combined application of those compounds or biological agents can significantly improve varied severe medical conditions.

Abstract: A method of proving safety and efficacy of herbal compounds by clinical information obtained by physicians in daily practice by implementation of network technology, chemical analysis, statistics, and clinical trials. Data for potential therapeutic compounds are directly obtained from human being in daily practice setting, application of the invention will tremendously reduce the time and costs involved in research and development of drugs.

Abstract: A system and method for acquiring and using inversion-recovery data and spectral data. In particular, the inversion-recovery data and spectral data can be used to determine adenosine triphosphate (ATP) hydrolysis rate of a subject without a quantification of inorganic phosphate.

Abstract: The present invention provides swine cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple cell types. Also provided are methods of isolation and culture, as well as uses for the cells, such as xenogeneic transplantation and/or tissue repair.

Abstract: The invention involves methods and materials related to fibrin-based biomatrices.

Abstract: The invention provides for methods of delivering compositions to an individual via the vasculature, and provides for a device that can be used to deliver compositions to an individual via the vasculature.

Abstract: The invention involves methods and materials related to fibrin-based biomatrices.